Amboy Street Invests in Millie’s $12M Series A

Amboy Street is excited to announce its latest investment in Millie - a midwifery-led, hybrid maternity clinic providing in-person and virtual care.

2021-2024: Active Acquirer Profiles in Women’s Health

We analyzed our annual Top 10 Deals blog series from 2021 - 2024 and identified the most active acquirer profiles in women’s health and sexual health.

Top 10 Deals of 2024: Ovarian Cancer Therapeutics Sold for $1.8B

For our last deal in the Top 10 Deals of 2024 series, we explore a major acquisition in women’s health biopharma - a deal that advances innovation in the treatment of ovarian cancer, one of the deadliest forms of the disease.

Amboy Street Invests in Endo Therapeutic - Gesynta Pharma’s $27M Round

Amboy Street Ventures is excited to announce its latest investment in Gesynta Pharma - developing a novel non-hormonal drug candidate for the treatment of endometriosis.

Top Deals of 2024: Flo Health Secures $200M in Funding to Achieve Unicorn Status

This blog highlights one of the largest growth capital investments made in Femtech this year. Led by General Atlantic, the deal highlights a growing interest in the women’s health sector from prominent generalist firms.

Top 10 Deals of 2024: Hologic Acquires Endomag for $310M

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Top 10 Deals of 2024: Hologic Acquires Uterine Fibroid Treatment Company for $350M

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

Top 10 Deals of 2024: Viatris sells Women's Health Line in $1.2B Deal

This week we delve into a major acquisition touching multiple areas of women’s health. A deal like this demonstrates a strong appetite for women’s health innovation, across indications, as acquirers recognize the financial viability in meeting these needs.

Fast track our industry.
Get in touch today.